3 ASX Biotech Stocks Fall: What Investors Should Know

Sonal Goyal

27 October 2026 04:27 PM AEDT

3 ASX Biotech Stocks Fall: What Investors Should Know

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Vectus Biosystems (ASX:VBS) traded at $0.08, down 11.11%. The FDA granted a pre-IND Type B meeting request for VB0004 in IPF.
Alterity Therapeutics (ASX:ATH) traded at $0.24, down 9.43%. The FY26 net loss was $23.40 million, up 92.6% from $12.15 million.
Identifai Genetics (ASX:ID1) traded at $0.35, down 10.26%. Identifai began trading on the ASX on 13 October 2026 after a $10 million IPO at $0.20 per share.

Shares in Vectus Biosystems Ltd (ASX:VBS), Alterity Therapeutics Ltd (ASX:ATH) and Identifai Genetics Ltd (ASX:ID1) were trading lower during the 27 October 2026 trading session: Vectus Biosystems at $0.08, down 11.11%; Alterity Therapeutics at $0.24, down 9.43%; Identifai Genetics at $0.35, down 10.26%. At the same time, the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Three biotechnology companies with fibrosis, neurodegeneration and prenatal screening programs traded lower.

Vectus Biosystems Ltd (ASX:VBS)

Vectus Biosystems shares traded at $0.08, down 11.11%, during the session. Vectus Biosystems said the FDA granted a pre-IND meeting for VB0004 in idiopathic pulmonary fibrosis, with written responses expected by mid-November 2026.

Alterity Therapeutics Ltd (ASX:ATH)

Alterity Therapeutics shares traded at $0.24, down 9.43%, during the session. Alterity Therapeutics reported an FY26 net loss of $23.4 million and year-end cash of $37.3 million in its audited Appendix 4E.

Identifai Genetics Ltd (ASX:ID1)

Identifai Genetics shares traded at $0.35, down 10.26%, during the session. Identifai Genetics listed on the ASX on 13 October 2026 after a $10 million IPO, to fund US laboratory readiness and clinical validation of its Windrose prenatal screening platform.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Biotechnology and specialty pharmaceutical companies report progress through regulatory meetings, clinical studies, licensing and Capital raisings.

Risks

Items noted in the companies’ materials include a pre-IND meeting provides feedback and does not approve a trial; the loss widened by more than 90% and net tangible assets per share declined; the company is at a pre-commercial stage, with validation studies and laboratory readiness still to be completed.

What Lies Ahead

The documents point to the following next steps: for Vectus Biosystems, submission of the meeting package, FDA written responses by mid-November 2026 and subsequent clinical and regulatory planning; for Alterity Therapeutics, the Form 20-F Annual Report for the review of operations, prospects, events since year end and risk factors; for Identifai Genetics, US laboratory readiness, a multicentre clinical validation study, staged product releases and commercial partnerships.

In Summary

VBS, ATH and ID1 fell during the session. Their latest documents cover a regulatory meeting, annual results and a listing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.